{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25","upperLimit":"141","value":"41"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"107","value":"88"},{"groupId":"OG002","lowerLimit":"8","upperLimit":"295","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Duration to hematologic improvement as determined by median duration of HI response.","dispersionType":"Full Range","groups":[{"description":"Patients with baseline platelet counts \\>50,000 k/uL received lenalidomide (LEN) PO daily or QOD on days 1-21. If platelet counts fell below 50,000 k/uL during treatment, patients discontinued LEN and received eltrombopag olamine (ELT) PO daily or QOD until platelet counts \\> 50,000 k/uL were achieved, and then maintained for 2 weeks thereafter. If a platelet count \\>50,000 k/uL was maintained, patients discontinued ELT and resumed only LEN as a single agent (PO daily or QOD). If platelets fell below 50,000 k/uL a second time, LEN was stopped and ELT was re-initiated at the dose last given to the patient. Once platelet counts were \\>50,000 k/uL and maintained for 2 weeks, patients resumed LEN concurrently with ELT for all subsequent courses.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG000","title":"Arm A (Platelets > 50,000 k/uL) LEN Initiation"},{"description":"Patients with baseline platelet counts \\<50,000 k/uL received eltrombopag olamine (ELT) PO daily or QOD on days 1-28 until a platelet count \\>50,000 k/uL was achieved. Once a platelet count\\>50,000 k/uL was achieved the ELT dose was maintained for two weeks. After two weeks ELT was discontinued and LEN was started as in Arm A (i.e., eltrombopag olamine discontinued and lenalidomide started). Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG001","title":"Arm B (Platelets < 50,000 k/uL) ELT Initiation With Potential LEN Combination"},{"description":"Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG002","title":"Arm C (Platelets < 50,000 k/uL) ELT Monotherapy"}],"paramType":"MEDIAN","populationDescription":"Intention to treat population study design.","reportingStatus":"POSTED","timeFrame":"Time to progression/relapse following hematologic improvement, at completion of final cycle and treatment discontinuation; up to 6 years","title":"Duration of Hematologic Improvement (HI)","type":"SECONDARY","unitOfMeasure":"number of weeks"}